Cardinal Manufactures 10% Gain In 1Q: Rx Stocks Stay Out Of Favor
Cardinal's expanding manufacturing capacity is enhancing its image with investors who are attracted to the pharmaceutical sector but wary of the risks of drug development
Cardinal's expanding manufacturing capacity is enhancing its image with investors who are attracted to the pharmaceutical sector but wary of the risks of drug development